NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Xoma Royalty Corporation XOMA
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$10.3M
▲ 55.6% vs FY2024
EPS · FY25
$1.46
Dividend / sh · FY25
—
Payout · FY25
17%
ROE · FY25
43.5%
Net margin · FY25
306.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 10.3M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
306 cents of every revenue dollar became profit this year.
Per share
USD 1.46
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
43.5%
Return on equity, FY2025
ROE
Operating margin110.0%
Net margin306.4%
Return on assets12.8%
Each USD of equity produced 43 cents of profit this year.
Returned to shareholders
USD 21.2M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 5.5M
Net buybacksUSD 15.7M
Share of profit66.8%
Consecutive raises—
USD 5.5M in dividends and USD 15.7M in buybacks — 67% of the year's profit went back to shareholders.
Growth
−18.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+35.6%
−18.0%
−15.5%
−7.6%
Net income
+19.0%
EPS, diluted
+13.4%
Returned to shareholders
+57.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+5.6%
Change, 10 years+99.2%
The share count grew 6% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 272.7M
total assets, end of FY2025
Total assetsUSD 272.7M
EquityUSD 83.9M
CashUSD 82.9M
Gross debtUSD 109.0M
Net debtUSD 26.1M
Current ratio3.37×
Net debt stands at 31% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.1
0.0
0.0
0.0
0.1
0.0
0.1
Operating income $B
0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
0.0
−0.1
−0.0
−0.1
−0.1
−0.1
−0.0
−0.1
0.0
EBITDA $B
·
·
·
·
·
·
·
−0.0
0.0
−0.1
−0.0
−0.1
−0.1
−0.1
−0.0
−0.1
0.0
Income tax $B
0.0
−0.0
0.0
−0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
Net income $B
0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
0.0
−0.1
−0.0
−0.0
−0.1
−0.1
−0.0
−0.1
0.0
EPS, diluted $
1.46
−1.65
−4.04
−1.98
0.65
0.78
−0.23
−1.59
0.73
−8.89
−3.50
−13.49
−1.43
−1.10
−1.04
−3.69
0.05
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
17
−40
−13
−32
22
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
43.5
−18.4
−38.4
−12.9
13.8
20.4
−6.3
−108.6
·
·
−5216.7
·
−1419.4
−389.6
−169.6
−334.4
3.1
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.12
0.11
0.08
0.04
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed